WO1999032152A3 - Methods for delivering pharmaceutical agents to mucosal surfaces - Google Patents

Methods for delivering pharmaceutical agents to mucosal surfaces Download PDF

Info

Publication number
WO1999032152A3
WO1999032152A3 PCT/US1998/027410 US9827410W WO9932152A3 WO 1999032152 A3 WO1999032152 A3 WO 1999032152A3 US 9827410 W US9827410 W US 9827410W WO 9932152 A3 WO9932152 A3 WO 9932152A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical agents
methods
incorporated
delivery system
mucosal surfaces
Prior art date
Application number
PCT/US1998/027410
Other languages
French (fr)
Other versions
WO1999032152A2 (en
Inventor
Vladimir Kharitonov
Helen M Ranney
Leo Trevino
Stephen G Flore
Luis A Dellamary
Lorraine E Reeve
Jeffry G Weers
Original Assignee
Mdv Tech Inc
Vladimir Kharitonov
Helen M Ranney
Leo Trevino
Stephen G Flore
Luis A Dellamary
Lorraine E Reeve
Jeffry G Weers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mdv Tech Inc, Vladimir Kharitonov, Helen M Ranney, Leo Trevino, Stephen G Flore, Luis A Dellamary, Lorraine E Reeve, Jeffry G Weers filed Critical Mdv Tech Inc
Priority to AU19438/99A priority Critical patent/AU1943899A/en
Publication of WO1999032152A2 publication Critical patent/WO1999032152A2/en
Publication of WO1999032152A3 publication Critical patent/WO1999032152A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Delivery systems and methods of delivering pharmaceutical agents to a hydrophobic region of an animal, particularly a mucosal surface, such as the mucosal lining of the gastrointestinal (GI) tract, are disclosed. In one embodiment, one or more pharmaceutical agents are incorporated into a delivery system comprising a constitutive polymer, such as a poloxamer, and, optionally, one or more modifier polymers (e.g., carboxymethylcellulose) and/or one or more hydrophilic co-surfactants (e.g., a fatty acid soap). In another embodiment, one or more pharmaceutical agents are incorporated into a delivery system comprising a reverse emulsion, which comprises a disperse polar phase, a continuous lipophilic phase, and one or more emulsifying agents (e.g., a surfactant). The disclosed compositions and methods are useful in the treatment of, for example, gastric H. pylori infection, where the incorporated pharmaceutical agent is an antibiotic.
PCT/US1998/027410 1997-12-23 1998-12-23 Methods for delivering pharmaceutical agents to mucosal surfaces WO1999032152A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19438/99A AU1943899A (en) 1997-12-23 1998-12-23 Methods for delivering pharmaceutical agents to mucosal surfaces

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US97/23865 1997-12-23
PCT/US1997/023865 WO1999032151A1 (en) 1997-12-23 1997-12-23 Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions

Publications (2)

Publication Number Publication Date
WO1999032152A2 WO1999032152A2 (en) 1999-07-01
WO1999032152A3 true WO1999032152A3 (en) 1999-12-09

Family

ID=22262364

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1997/023865 WO1999032151A1 (en) 1997-12-23 1997-12-23 Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
PCT/US1998/027410 WO1999032152A2 (en) 1997-12-23 1998-12-23 Methods for delivering pharmaceutical agents to mucosal surfaces

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1997/023865 WO1999032151A1 (en) 1997-12-23 1997-12-23 Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions

Country Status (5)

Country Link
EP (1) EP1039932A1 (en)
JP (1) JP2001526246A (en)
AU (2) AU753206B2 (en)
CA (1) CA2316248A1 (en)
WO (2) WO1999032151A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887076A3 (en) * 1997-05-07 1999-03-31 Saturnus A.G. Adhesion prevention and an endoscopic insufflation system therefor
WO2002085337A1 (en) 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
EP1414497A4 (en) * 2001-08-08 2007-11-21 Univ Florida Novel microemulsion and micelle systems for solubilizing drugs
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
EP1539282A2 (en) * 2002-08-06 2005-06-15 GenVec, Inc. Improved injection system
US7223826B2 (en) 2003-01-30 2007-05-29 3M Innovative Properties Company Amide-functional polymers, compositions, and methods
US20040151691A1 (en) 2003-01-30 2004-08-05 Oxman Joel D. Hardenable thermally responsive compositions
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
JP4473539B2 (en) * 2003-08-12 2010-06-02 エスエス製薬株式会社 Pharmaceutical composition
WO2005079856A1 (en) * 2004-02-23 2005-09-01 The University Of British Columbia Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules
US20090196844A1 (en) 2006-02-01 2009-08-06 Samyang Corporation Composition for inhibiting adhesion
US8062282B2 (en) 2006-02-13 2011-11-22 Fossa Medical, Inc. Methods and apparatus for temporarily occluding body openings
CA2723458C (en) 2008-05-14 2014-01-28 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
KR101367479B1 (en) * 2008-07-21 2014-03-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
JP2013508381A (en) * 2009-10-21 2013-03-07 オトノミ―,インク. Control of the gelation temperature of formulations containing poloxamers
JP6143286B2 (en) * 2013-05-13 2017-06-07 学校法人 関西大学 Anti-adhesion material and method for producing the same
SG11201609593RA (en) * 2014-05-16 2016-12-29 Ultrast Inc Phase-shifting formulations
US10105387B2 (en) 2014-07-24 2018-10-23 Medytox Inc. Temperature sensitive adhesion prevention composition and use thereof
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. Otic gel formulations for treating otitis externa
JP6403297B2 (en) * 2017-05-02 2018-10-10 川澄化学工業株式会社 Method for producing anti-adhesion material

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274431A2 (en) * 1987-01-08 1988-07-13 Quixote Corporation Drug delivery compositions and methods
WO1990004971A1 (en) * 1988-11-03 1990-05-17 M.D.R. Group, Inc. Improved viscoelastic fluid for use in surgery and other therapies and method of using same
EP0455396A1 (en) * 1990-05-01 1991-11-06 MDV Technologies, Inc. Aqueous gel compositions and their use
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
WO1994003157A1 (en) * 1992-07-28 1994-02-17 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
EP0598116A1 (en) * 1989-11-27 1994-05-25 Nippon Shinyaku Company, Limited Fat emulsion
WO1994014415A1 (en) * 1992-12-24 1994-07-07 Hemagen/Pfc Fluorocarbon emulsions
US5369131A (en) * 1991-04-24 1994-11-29 Poli Industria Chimica S.P.A. Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
WO1995009626A1 (en) * 1993-10-01 1995-04-13 Syntex (U.S.A.) Inc. Mycophenolate mofetil high dose oral suspensions
WO1995024430A2 (en) * 1994-03-04 1995-09-14 University Of Washington Block and graft copolymers and methods relating thereto
US5484610A (en) * 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
EP0694310A1 (en) * 1993-04-16 1996-01-31 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
WO1996020696A1 (en) * 1994-12-30 1996-07-11 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810503A (en) * 1987-03-31 1989-03-07 Basf Corporation Polymers which form gels at low concentrations in water
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
JP2926749B2 (en) * 1989-04-25 1999-07-28 吉富製薬株式会社 Prostaglandin-containing liquid composition
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274431A2 (en) * 1987-01-08 1988-07-13 Quixote Corporation Drug delivery compositions and methods
WO1990004971A1 (en) * 1988-11-03 1990-05-17 M.D.R. Group, Inc. Improved viscoelastic fluid for use in surgery and other therapies and method of using same
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
EP0598116A1 (en) * 1989-11-27 1994-05-25 Nippon Shinyaku Company, Limited Fat emulsion
EP0455396A1 (en) * 1990-05-01 1991-11-06 MDV Technologies, Inc. Aqueous gel compositions and their use
US5484610A (en) * 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
US5369131A (en) * 1991-04-24 1994-11-29 Poli Industria Chimica S.P.A. Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
WO1994003157A1 (en) * 1992-07-28 1994-02-17 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
WO1994014415A1 (en) * 1992-12-24 1994-07-07 Hemagen/Pfc Fluorocarbon emulsions
EP0694310A1 (en) * 1993-04-16 1996-01-31 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
WO1995009626A1 (en) * 1993-10-01 1995-04-13 Syntex (U.S.A.) Inc. Mycophenolate mofetil high dose oral suspensions
WO1995024430A2 (en) * 1994-03-04 1995-09-14 University Of Washington Block and graft copolymers and methods relating thereto
WO1996020696A1 (en) * 1994-12-30 1996-07-11 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders

Also Published As

Publication number Publication date
WO1999032152A2 (en) 1999-07-01
JP2001526246A (en) 2001-12-18
AU5533598A (en) 1999-07-12
WO1999032151A1 (en) 1999-07-01
AU1943899A (en) 1999-07-12
EP1039932A1 (en) 2000-10-04
AU753206B2 (en) 2002-10-10
CA2316248A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
WO1999032152A3 (en) Methods for delivering pharmaceutical agents to mucosal surfaces
RU2227018C2 (en) Polymethylidenemalonate-base new microspheres, methods for their preparing and pharmaceutical compositions containing thereof
JP4157969B2 (en) Emulsified drug delivery system
JP5600233B2 (en) Compositions of lipids and cationic peptides
NZ506415A (en) Liquid polymeric compositions for controlled release of bioactive substances using a polymer to active agent ratio of less than 1:1
PT97370A (en) PROCESS FOR THE PREPARATION OF A CONTROLLED LIBERATION FORMULA IN THE FORM OF A PLURALITY OF MULTIDOSE UNITS
CA2066384A1 (en) Gastrointestinal mucosa-adherent matrixes, pharmaceutical preparation and a coating composition
CA2313024A1 (en) Pharmaceutical compositions containing an omega-3 fatty acid oil
CA2417800A1 (en) Novel microemulsion and micelle systems for solubilizing drugs
CA2181502A1 (en) Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
WO2004043513A3 (en) Surface dissolution and/or bulk erosion controlled release compositions and devices
CA2330330A1 (en) Pharmaceutical compositions comprising an amphoteric surfactant an alkoxylated cetyl alcohol and a polar drug
JP2003503440A (en) Pharmaceutical composition containing clear oil
ZA200204268B (en) Gastroretentive controlled release pharmaceutical dosage forms.
WO1998047491A3 (en) Controlled release formulations using intelligent polymers
WO2003022252A3 (en) Combinatorial type (several vehicles within a housing) controlled release drug delivery device
EP2298283A3 (en) Pharmaceutical formulations comprising cannabinoids
CA2340056A1 (en) Pharmaceutical compositions containing lipase inhibitors
HUP0303290A2 (en) Insecticidal oil-in-water emulsion formulation, preparation and use thereof
SE0202619D0 (en) New Polymers and Applications
BR9908616A (en) Gastric and / or duodenal adhesive pharmaceutical composition.
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
DZ2316A1 (en) Pharmaceutical micro spheres of valproic acid for oral administration.
CA2358448A1 (en) Dispersible concentrate for the delivery of cyclosporin
ATE322250T1 (en) SELF-EMULSIFYING SYSTEM FOR DRUG DELIVERY OF FAT-SOLUBLE ACTIVE INGREDIENTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase